NLRP3 and early-onset autosomal dominant Alzheimer disease: In that sense, our results might provide a basis for developing potential therapies for diseases that are mediated by NLRP3 inflammasome activation and autophagy impairment in macrophages, such as atherosclerosis [61], diabetes mellitus [62, 63], Crohn's disease [64], Alzheimer's disease [65], uveitis [66] and age-related macular degeneration [67].